欺诈发行！思创医惠遭公安机关调查取证

Core Viewpoint - Sichuan Medical Technology Co., Ltd. (hereinafter referred to as "the company" or "Sichuan Medical") is under investigation by the Hangzhou Public Security Bureau for suspected fraudulent issuance of securities, with evidence collection initiated [1] Group 1: Company Investigation and Legal Actions - The company received a notice from the Hangzhou Public Security Bureau regarding the collection of evidence related to a fraud case involving securities issuance [1] - The Zhejiang Securities Regulatory Commission previously issued an administrative penalty and market ban against the company, citing that it inflated revenue and profits through false business activities, resulting in a cumulative inflated revenue of 34.93 million yuan and inflated profits of 33.02 million yuan in 2019, which accounted for 20.03% of the total profit for that period [1] - For the period from January to September 2020, the company inflated revenue by 60.96 million yuan and profits by 52.37 million yuan, which constituted 56.81% of the total profit for that period [1] Group 2: Investor Compensation - Investors who purchased Sichuan Medical shares between April 30, 2020, and October 28, 2022, and still hold the shares, may voluntarily register for compensation through the "Sina Investor Rights Protection Platform" [2][3] - The time limit for filing claims related to the securities false statement case is only two months remaining, urging affected investors to act promptly [2]